Table 1.
Number of all cases, metastatic cases and cases with liver metastasis and incidence, distribution and prognosis of liver metastasis by cancer type
| Categories | Number of cases | Incidence | Distribution | Median survival with IQR | ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
||||
| Site | Subsite | All | Metastasis | LM | LM | LM/metastasisa | Distribution of LM casesb | LM |
| Brain | Brain | 22991 | 180 | 11 | 0.05% | 6.11% | 0.01% | 13 (4-20) |
| Head and neck | Head and neck | 67219 | 2728 | 489 | 0.73% | 17.93% | 0.46% | 7 (2-17) |
| Thyroid | Thyroid | 65892 | 1316 | 130 | 0.20% | 9.88% | 0.12% | 6 (2-31) |
| Breast | All breast | 307512 | 16714 | 4527 | 1.47% | 27.09% | 4.30% | 15 (2-40) |
| Her2-/HR+ | 208447 | 8466 | 1684 | 0.81% | 19.89% | 1.60% | 19 (5-39) | |
| Her2+/HR- | 13506 | 1330 | 624 | 4.62% | 46.92% | 0.59% | 27 (4-62) | |
| Her2+/HR+ | 31230 | 2445 | 904 | 2.89% | 36.97% | 0.86% | 30 (6-NA) | |
| Triple negative | 32244 | 1980 | 569 | 1.76% | 28.74% | 0.54% | 8 (2-16) | |
| Unknown status | 22085 | 2493 | 746 | 3.38% | 29.92% | 0.71% | 2 (0-17) | |
| Lung | All lung | 212433 | 110216 | 26939 | 12.68% | 24.44% | 25.58% | 2 (0-8) |
| Adenocarcinoma | 80255 | 46202 | 7848 | 9.78% | 16.99% | 7.45% | 3 (1-9) | |
| Squamous cancer | 41861 | 14893 | 2741 | 6.55% | 18.40% | 2.60% | 3 (1-7) | |
| SCLC | 26792 | 18611 | 8688 | 32.43% | 46.68% | 8.25% | 3 (0-9) | |
| Other | 63525 | 30510 | 7662 | 12.06% | 25.11% | 7.27% | 1 (0-5) | |
| GI | Oesophagus | 17475 | 5785 | 2884 | 16.50% | 49.85% | 2.74% | 4 (1-10) |
| Stomach | 27799 | 10179 | 4577 | 16.46% | 44.97% | 4.35% | 4 (1-11) | |
| Biliary tract | 17157 | 5921 | 3911 | 22.80% | 66.05% | 3.71% | 3 (1-9) | |
| All pancreas | 46276 | 23724 | 18490 | 39.96% | 77.94% | 17.55% | 2 (1-7) | |
| Head of pancreas | 24975 | 9242 | 7151 | 28.63% | 77.38% | 6.79% | 3 (1-8) | |
| Body of pancreas | 6894 | 4139 | 3165 | 45.91% | 76.47% | 3.00% | 3 (1-8) | |
| Tail of pancreas | 7792 | 5591 | 4524 | 58.06% | 80.92% | 4.30% | 2 (1-7) | |
| Unspecified pancreas | 6615 | 4752 | 3650 | 55.18% | 76.81% | 3.47% | 1 (0-5) | |
| Small intestine | 8288 | 2237 | 1449 | 17.48% | 64.77% | 1.38% | 30 (4-NA) | |
| Colon & rectum | 163055 | 34703 | 26083 | 16.00% | 75.16% | 24.76% | 12 (3-29) | |
| Right colon | 67014 | 13608 | 10017 | 14.95% | 73.61% | 9.51% | 10 (2-23) | |
| Left colon | 53756 | 12055 | 9355 | 17.40% | 77.60% | 8.88% | 16 (4-35) | |
| Unspecified colon | 3265 | 2341 | 1774 | 54.33% | 75.78% | 1.68% | 2 (0-8) | |
| Rectum | 39020 | 6699 | 4937 | 12.65% | 73.70% | 4.69% | 17 (6-33) | |
| Anus | 6692 | 441 | 198 | 2.96% | 44.90% | 0.19% | 15 (6-27) | |
| Other GI | 13400 | 6101 | 3982 | 29.72% | 65.27% | 3.78% | 2 (1-9) | |
| GU | Kidney | 66654 | 9807 | 2274 | 3.41% | 23.19% | 2.16% | 3 (1-10) |
| Bladder | 35200 | 2880 | 705 | 2.00% | 24.48% | 0.67% | 2 (1-7) | |
| Prostate | 270500 | 15520 | 741 | 0.27% | 4.77% | 0.70% | 10 (4-22) | |
| Testis | 13359 | 1492 | 252 | 1.89% | 16.89% | 0.24% | 25 (6-NA) | |
| Other GU | 5324 | 509 | 173 | 3.25% | 33.99% | 0.16% | 2 (0-9) | |
| GYN | Ovary | 27023 | 7288 | 1957 | 7.24% | 26.85% | 1.86% | 12 (2-40) |
| Endometrium | 61478 | 3593 | 551 | 0.90% | 15.34% | 0.52% | 5 (1-16) | |
| Cervix | 3651 | 335 | 40 | 1.10% | 11.94% | 0.04% | 10.0 (2.5-15.0) | |
| Uterus | 16720 | 2638 | 476 | 2.85% | 18.04% | 0.45% | 4 (1-11) | |
| Other GYN | 8678 | 961 | 186 | 2.14% | 19.35% | 0.18% | 10 (2-49) | |
| Melanoma | Melanoma | 94544 | 2023 | 593 | 0.63% | 29.31% | 0.56% | 4 (2-10) |
| Sarcoma | Sarcoma | 29780 | 4930 | 1373 | 4.61% | 27.85% | 1.30% | 9 (2-33) |
| All other | All other | 21625 | 5199 | 2338 | 10.81% | 44.97% | 2.22% | 1 (0-7) |
| All | All | 1630725 | 277420 | 105329 | 6.46% | 37.96% | 100% | 4 (1-14) |
a
The ratios here represent the percentage of liver metastasis cases over metastatic cases.
b
These data represent the percentage of liver metastasis from a specific original site over all liver metastasis cases.
For instance, 0.01% of liver metastasis are originated from brain. Abbreviations: IQR: interquartile range; LM: liver metastasis; HER-2: Human epidermal growth factor receptor-2; HR: hormone receptor; SCLC: small cell lung cancer; GI: gastrointestinal cancer; GU: genitourinary cancer; GYN: gynaecologic cancer.